RxDoctor Payments Data

Gregg Pressman, MD

Cardiovascular Disease · Philadelphia, PANPI 1528064888

Payments from drug & device makers

$128,829in general payments, 2019–2025

Across 89 payments — averaging $1447.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eko Health, Inc.$58K
  • Lantheus Medical Imaging, Inc.$37K
  • AstraZeneca$18K
  • Jazz Pharmaceuticals Inc.$10K
  • Abbott$3K
  • Edwards Lifesciences$2K
  • plus $947 from 7 others

What the payments were for

  • Consulting fees$9,06358%
  • Travel & lodging$3,15320%
  • Food & beverage$3,07220%
  • Other$4293%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$128,829 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$56,330
Medicare patients
311
Services billed
771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan40$55,543
FarxigaDapagliflozin Propanediol36$43,193
EliquisApixaban31$39,615
XareltoRivaroxaban26$32,390
Rosuvastatin Calcium114$4,236
Nifedipine ErNifedipine92$3,210
Ezetimibe104$3,113
Spironolactone-HctzSpironolact/Hydrochlorothiazid43$1,866
Atorvastatin Calcium124$1,769
Chlorthalidone58$1,374
Bumetanide17$1,043
Metoprolol Tartrate24$751
Carvedilol61$653
Potassium Chloride27$546
ClopidogrelClopidogrel Bisulfate41$473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$41$55,54340 claims
AstraZenecaFarxiga$18,124$43,19336 claims
PfizerEliquis$27$39,61531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →